Segment Wealth Management LLC Invests $4.83 Million in Cencora, Inc. $COR

Segment Wealth Management LLC bought a new stake in Cencora, Inc. (NYSE:COR) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 15,453 shares of the company’s stock, valued at approximately $4,830,000.

A number of other large investors have also bought and sold shares of COR. Norges Bank bought a new position in Cencora in the 2nd quarter valued at $695,215,000. Artisan Partners Limited Partnership bought a new stake in shares of Cencora during the second quarter worth $411,888,000. Vanguard Group Inc. increased its stake in shares of Cencora by 5.3% in the second quarter. Vanguard Group Inc. now owns 22,479,041 shares of the company’s stock valued at $6,740,340,000 after buying an additional 1,125,661 shares in the last quarter. Viking Global Investors LP raised its holdings in shares of Cencora by 95.0% in the second quarter. Viking Global Investors LP now owns 2,081,732 shares of the company’s stock valued at $624,207,000 after buying an additional 1,013,913 shares during the last quarter. Finally, Ameriprise Financial Inc. lifted its position in Cencora by 228.6% during the 2nd quarter. Ameriprise Financial Inc. now owns 974,505 shares of the company’s stock worth $292,207,000 after buying an additional 677,952 shares in the last quarter. 97.52% of the stock is currently owned by institutional investors.

Cencora Price Performance

COR opened at $340.08 on Tuesday. The company has a fifty day moving average price of $348.91 and a two-hundred day moving average price of $315.59. The firm has a market capitalization of $65.97 billion, a PE ratio of 42.78, a P/E/G ratio of 1.62 and a beta of 0.63. Cencora, Inc. has a 52 week low of $223.92 and a 52 week high of $377.54. The company has a debt-to-equity ratio of 4.32, a quick ratio of 0.55 and a current ratio of 0.90.

Cencora (NYSE:COR) last posted its quarterly earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share for the quarter, beating analysts’ consensus estimates of $3.79 by $0.05. Cencora had a return on equity of 227.15% and a net margin of 0.48%.The company had revenue of $83.73 billion for the quarter, compared to the consensus estimate of $83.36 billion. During the same quarter in the prior year, the business posted $3.34 EPS. The firm’s quarterly revenue was up 5.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. As a group, analysts anticipate that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, December 1st. Stockholders of record on Friday, November 14th were given a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. The ex-dividend date was Friday, November 14th. This is an increase from Cencora’s previous quarterly dividend of $0.55. Cencora’s dividend payout ratio is presently 30.19%.

Insider Activity

In related news, EVP Silvana Battaglia sold 1,677 shares of the stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $345.00, for a total value of $578,565.00. Following the sale, the executive vice president directly owned 18,796 shares in the company, valued at $6,484,620. This trade represents a 8.19% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Robert P. Mauch sold 5,096 shares of Cencora stock in a transaction that occurred on Thursday, December 18th. The stock was sold at an average price of $343.45, for a total transaction of $1,750,221.20. Following the transaction, the chief executive officer directly owned 68,059 shares in the company, valued at $23,374,863.55. The trade was a 6.97% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 20,317 shares of company stock valued at $7,009,260 in the last ninety days. 10.80% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the stock. TD Cowen raised their price objective on shares of Cencora from $350.00 to $400.00 and gave the company a “buy” rating in a research report on Monday, November 10th. JPMorgan Chase & Co. increased their price target on shares of Cencora from $344.00 to $417.00 and gave the company an “overweight” rating in a research note on Tuesday, November 11th. UBS Group raised their price target on shares of Cencora from $380.00 to $415.00 and gave the company a “buy” rating in a report on Friday, November 7th. Barclays initiated coverage on Cencora in a report on Monday, December 8th. They set an “overweight” rating and a $400.00 price objective on the stock. Finally, Robert W. Baird set a $392.00 price objective on Cencora in a research report on Tuesday, December 16th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, Cencora has an average rating of “Moderate Buy” and an average target price of $373.25.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.